Nuclear Receptor NURR1 Functions to Promote Stemness and Epithelial-mesenchymal Transition in Prostate Cancer Via Its Targeting of Wnt/β-catenin Signaling Pathway

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2024 Mar 27

PMID 38531859

Authors

Xingxing Zhang

Haolong Li

Yuliang Wang

Hui Zhao

Zhu Wang

Franky Leung Chan

Affiliations

Soon will be listed here.

Abstract

Dysregulated activation of Wnt/β-catenin signaling pathway is a frequent or common event during advanced progression of multiple cancers. With this signaling activation, it enhances their tumorigenic growth and facilitates metastasis and therapy resistance. Advances show that this signaling pathway can play dual regulatory roles in the control of cellular processes epithelial-mesenchymal transition (EMT) and cancer stemness in cancer progression. Aberrant activation of Wnt/β-catenin signaling pathway is shown to be common in prostate cancer and also castration-resistant prostate cancer (CRPC). However, the transcriptional regulators of this pathway in prostate cancer are still not well characterized. NURR1 (NR4A2) is an orphan nuclear receptor and plays an important role in the development of dopaminergic neurons. Previously, we have shown that NURR1 exhibits an upregulation in isolated prostate cancer stem-like cells (PCSCs) and a xenograft model of CRPC. In this study, we further confirmed that NURR1 exhibited an upregulation in prostate cancer and also enhanced expression in prostate cancer cell lines. Functional and molecular analyses showed that NURR1 could act to promote both in vitro (cancer stemness and EMT) and also in vivo oncogenic growth of prostate cancer cells (metastasis and castration resistance) via its direct transactivation of CTNNB1 (β-catenin) and activation of β-catenin to mediate the activation of Wnt/β-catenin signaling pathway. Moreover, we also demonstrated that NURR1 activity in prostate cancer cells could be modulated by small molecules, implicating that NURR1 could be a potential therapeutic target for advanced prostate cancer management.

Citing Articles

PMAIP1 regulates the progression of follicular thyroid carcinoma through the Wnt3/FOSL1 pathway.

Wang H, Shang F, Wang Y, Pang B, Kang L, Zhou C Front Oncol. 2025; 15:1502391.

PMID: 39944827 PMC: 11814205. DOI: 10.3389/fonc.2025.1502391.

References

Kaplan Z, Zielske S, Ibrahim K, Cackowski F . Wnt and β-Catenin Signaling in the Bone Metastasis of Prostate Cancer. Life (Basel). 2021; 11(10). PMC: 8537160. DOI: 10.3390/life11101099. View

Masiello D, Chen S, Xu Y, Verhoeven M, Choi E, Hollenberg A . Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol. 2004; 18(10):2388-401. DOI: 10.1210/me.2003-0436. View

Tsao T, Beretov J, Ni J, Bai X, Bucci J, Graham P . Cancer stem cells in prostate cancer radioresistance. Cancer Lett. 2019; 465:94-104. DOI: 10.1016/j.canlet.2019.08.020. View

De La Taille A, Rubin M, Chen M, Vacherot F, Gil-Diez de Medina S, Burchardt M . Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res. 2003; 9(5):1801-7. View

Wang Z, Wu D, Ng C, Teoh J, Yu S, Wang Y . Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer. Endocr Relat Cancer. 2017; 25(1):35-50. DOI: 10.1530/ERC-17-0280. View

Whitaker H, Girling J, Warren A, Leung H, Mills I, Neal D . Alterations in beta-catenin expression and localization in prostate cancer. Prostate. 2008; 68(11):1196-205. DOI: 10.1002/pros.20780. View

. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015; 163(4):1011-25. PMC: 4695400. DOI: 10.1016/j.cell.2015.10.025. View

Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima F . Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. Eur Urol. 2019; 77(1):14-21. PMC: 6893106. DOI: 10.1016/j.eururo.2019.05.032. View

Nusse R, Clevers H . Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017; 169(6):985-999. DOI: 10.1016/j.cell.2017.05.016. View

10.

Truica C, Byers S, Gelmann E . Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 2000; 60(17):4709-13. View

11.

Law S, Conneely O, Demayo F, OMalley B . Identification of a new brain-specific transcription factor, NURR1. Mol Endocrinol. 1992; 6(12):2129-35. DOI: 10.1210/mend.6.12.1491694. View

12.

Uysal-Onganer P, Kawano Y, Caro M, Walker M, Diez S, Darrington R . Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer. 2010; 9:55. PMC: 2846888. DOI: 10.1186/1476-4598-9-55. View

13.

Dehm S, Hillman D, Sicotte H, Tan W, Gormley M, Bhargava V . A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol. 2017; 29(2):352-360. PMC: 6304474. DOI: 10.1093/annonc/mdx689. View

14.

Hedrick E, Safe S . Transforming Growth Factor β/NR4A1-Inducible Breast Cancer Cell Migration and Epithelial-to-Mesenchymal Transition Is p38α (Mitogen-Activated Protein Kinase 14) Dependent. Mol Cell Biol. 2017; 37(18). PMC: 5574050. DOI: 10.1128/MCB.00306-17. View

15.

Sharpe B, Beresford M, Bowen R, Mitchard J, Chalmers A . Searching for prostate cancer stem cells: markers and methods. Stem Cell Rev Rep. 2013; 9(5):721-30. DOI: 10.1007/s12015-013-9453-4. View

16.

Guo J, Zu G, Zhou T, Xing J, Wang Z . Clinicopathological significance of orphan nuclear receptor Nurr1 expression in gastric cancer. Clin Transl Oncol. 2015; 17(10):788-94. DOI: 10.1007/s12094-015-1305-z. View

17.

Zhang L, Cen L, Qu S, Wei L, Mo M, Feng J . Enhancing Beta-Catenin Activity via GSK3beta Inhibition Protects PC12 Cells against Rotenone Toxicity through Nurr1 Induction. PLoS One. 2016; 11(4):e0152931. PMC: 4821554. DOI: 10.1371/journal.pone.0152931. View

18.

Llopis S, Singleton B, Duplessis T, Carrier L, Rowan B, Williams C . Dichotomous roles for the orphan nuclear receptor NURR1 in breast cancer. BMC Cancer. 2013; 13:139. PMC: 3617898. DOI: 10.1186/1471-2407-13-139. View

19.

Chu J, Yu S, Hayward S, Chan F . Development of a three-dimensional culture model of prostatic epithelial cells and its use for the study of epithelial-mesenchymal transition and inhibition of PI3K pathway in prostate cancer. Prostate. 2008; 69(4):428-42. DOI: 10.1002/pros.20897. View

20.

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View